New Research Exploring FAK Inhibitors to Prevent Osteosarcoma Lung Metastasis
Researchers are exploring a new strategy to stop osteosarcoma from spreading to the lungs, one of the biggest challenges in treating this aggressive bone cancer.
A team at Colorado State University’s Flint Animal CancerA disease where cells divide and grow uncontrollably and can spread to other areas of the body. Center has received a major research grant from the US National Institutes of Health to investigate how drugs called FAK inhibitorsA drug that blocks or reduces the function of a particular protein. could improve outcomes for osteosarcoma patients.
The research focuses on understanding how osteosarcoma spreads through the body and whether disrupting that process could slow or prevent metastasis.
Why Lung Metastasis Matters
Osteosarcoma is an aggressive cancer that often spreads to the lungs early in the disease. Once metastasis occurs, treatment options become more limited and survival rates decrease.
Even when patients receive surgery and chemotherapy, tiny cancer deposits in the lungs can already be present but too small to detect on scans. These microscopic metastases are one of the main reasons osteosarcoma remains difficult to cure.
Understanding how cancer prepares the lungs for metastasis is therefore a major focus for researchers.
The “Seed and Soil” Problem
More than a century ago, scientists proposed the “seed and soil” theory of cancer spread. In simple terms, cancer cells (the “seeds”) grow best in certain environments (the “soil”).
For osteosarcoma, the lungs are the most common site where these seeds take hold.
Researchers believe tumours may send signals through the bloodstream that change the lung environment before cancer cells even arrive. This creates what scientists call a “pre-metastatic niche”, a supportive environment where cancer cells can later grow.
Stopping this process could be key to preventing metastasis.
Targeting a Key Cancer Signal: FAK
The new research focuses on a protein called focal adhesion kinase (FAK).
FAK acts as a signalling molecule inside cells and helps control processes such as cell movement, growth, and survival. Scientists have found that this pathway is often highly active in osteosarcoma tumour cells and in surrounding cells that support metastasis.
By blocking FAK using specialised drugs called FAK inhibitors, researchers hope to disrupt two important processes at the same time:
• The growth and survival of cancer cells
• The supportive environment in the lungs that allows metastases to form
In other words, the therapy could target both the “seed” and the “soil”.
Testing the Approach in Dogs
A unique aspect of this research is that it uses naturally occurring osteosarcoma in dogs.
Dogs develop osteosarcoma far more frequently than humans, and the disease behaves very similarly in both species. This makes canine osteosarcoma a powerful model for studying new treatments.
Researchers plan to test FAK inhibitors alongside standard chemotherapy in dogs with osteosarcoma to see whether the combination can reduce or delay lung metastases.
If the results are promising, the findings could help guide future clinical trials in human patients.
What This Could Mean for the Future
FAK inhibitors are already being studied in other cancers such as ovarian and pancreatic cancer, which means these drugs are not entirely new to oncology research.
If this approach proves effective in osteosarcoma, it could open the door to new treatment strategies focused on preventing metastasis rather than only treating established disease.
While this research is still in its early stages, it represents an important step toward understanding how osteosarcoma spreads and how that process might be stopped.
For patients and families affected by osteosarcoma, advances like these highlight the importance of continued research into the biology of the disease and the development of new targeted therapies.